Publicaciones (158) Publicaciones en las que ha participado algún/a investigador/a

2023

  1. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  2. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  3. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  4. International on-line questionnaire about severe lower gastrointestinal bleeding management: Do we have it clear?

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 4, pp. 282-287

  5. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  6. Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study

    Journal of Cancer Research and Therapeutics, Vol. 19, Núm. 5, pp. 1345-1349

  7. Role of Artificial Intelligence in Colonoscopy Detection of Advanced Neoplasias : A Randomized Trial

    Annals of internal medicine, Vol. 176, Núm. 9, pp. 1145-1152

  8. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

  9. Stent as bridge to surgery decreases postoperative complications without worsening oncological outcomes: retrospective unicentric cohort study and stent placement protocol

    Surgical Endoscopy, Vol. 37, Núm. 8, pp. 6298-6307

2022

  1. Co-09. Efectividad y seguridad de ustekinumab en enfermedad de crohn en pacientes bionaive: Un estudio multicéntrico

    Revista andaluza de patología digestiva, Vol. 45, Núm. 5, pp. 206-208

  2. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  3. Factors associated with lesion detection in colonoscopy among different indications

    United European Gastroenterology Journal, Vol. 10, Núm. 9, pp. 1008-1019

  4. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  5. Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 2, pp. 103-106

  6. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  7. Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676

  8. Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion

    Pharmaceuticals, Vol. 15, Núm. 1

  9. Regorafenib and trifluridine/tipiracil in real clinical practice

    Journal of cancer research and therapeutics, Vol. 18, pp. S367-S373

  10. Retrospective cohort study of laparoscopic ICG-Guided Lymphadenectomy in gastric cancer from a Western country center

    Surgical Endoscopy, Vol. 36, Núm. 11, pp. 8164-8169